Stem Cell Therapy: Mixed Results in Managing Osteoarthritis Pain for Seniors

This study was a systematic review and meta-analysis, meaning the authors gathered and combined results from multiple high-quality trials to get a clearer overall answer.

• Study design (in simple terms): The authors searched major medical databases up to May 6, 2024 and included randomized controlled trials in knee osteoarthritis. MSC injections (from bone marrow, fat tissue, or umbilical cord sources) were compared with placebo or other non-surgical approaches. Outcomes focused on pain (VAS) and function (WOMAC), converted to a 0–100 scale.

• Key findings (with numbers): 18 studies (1,174 total participants; 633 received MSCs) were included. Overall, MSCs were better than placebo for pain relief and function improvement at 12 months. The difference in treatment-related adverse events was not significant versus controls. Doses varied widely (about 1 million to 150 million cells per injection), and most studies followed people for 6–12 months (only one reached 24 months).

• Limitations to know: Results differed across studies (“high heterogeneity”), and some trials had weaknesses such as imperfect allocation concealment or incomplete blinding. The follow-up was generally short, so long-term benefits and risks are still uncertain.

• Practical implications for daily life: MSC injections may reduce pain and improve movement for some seniors, potentially supporting walking, stairs, and daily activities. But they are not proven to stop arthritis progression, and results may depend on the product type, dose, and your arthritis severity.

If you’re considering stem cell treatment, discuss it with your healthcare provider—ask about expected benefits, realistic timelines, side effects, product regulation/quality, cost, and how it compares with proven options like exercise therapy, weight management, medications, injections, or surgery when appropriate.